EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES

被引：7

作者：

Morand, E. F. ^{[1
]}

Tanaka, Y. ^{[2
]}

Furie, R. ^{[3
,4
]}

Vital, E. ^{[5
]}

van Vollenhoven, R. ^{[6
]}

Kalunian, K. ^{[7
]}

Mosca, M. ^{[8
]}

Doerner, T. ^{[9
]}

Wallace, D. J. ^{[10
]}

Silk, M. ^{[11
]}

Dickson, C. ^{[11
]}

De la Torre, I. ^{[11
]}

Meszaros, G. ^{[11
]}

Jia, B. ^{[11
]}

Crowe, B. ^{[11
]}

Petri, M. A. ^{[12
]}

机构：

[1] Monash Univ, Ctr Inflammatory Dis, Melbourne, Australia

[2] Univ Occupat & Environm Hlth, Dept Internal Med 1, Kitakyushu, Japan

[3] Northwell Hlth, New Hyde Pk, NY USA

[4] Northwell, Zucker Sch Med, Div Rheumatol, New Hyde Pk, NY USA

[5] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England

[6] Univ Med Ctr, Clin Immunol & Rheumatol, Amsterdam, Netherlands

[7] Univ Calif La Jolla, Div Rheumatol Allergy & Immunol, La Jolla, CA USA

[8] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy

[9] Charite, Dept Med Rheumatol & Clin Immunol, Berlin, Germany

[10] Univ Calif Los Angeles, Cedars Sinai Med Center, Div Rheumatol Allergy & Immunol, Los Angeles, CA USA

[11] Eli Lilly & Co, NIA, Indianapolis, IN USA

[12] Johns Hopkins Univ, Div Rheumatol, Sch Med, Baltimore, MD USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷

关键词：

D O I：

10.1136/annrheumdis-2022-eular.1968

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0190

引用

页码：327 / 328

页数：2

共 50 条

[1] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Wallace, Daniel J.
Furie, Richard A.
Tanaka, Yoshiya
Kalunian, Kenneth C.
Mosca, Marta
Petri, Michelle A.
Doerner, Thomas
Cardiel, Mario H.
Bruce, Ian N.
Gomez, Elisa
Carmack, Tara
DeLozier, Amy M.
Janes, Jonathan M.
Linnik, Matthew D.
de Bono, Stephanie
Silk, Maria E.
Hoffman, Robert W.
LANCET, 2018, 392 (10143): : 222 - 231
[2] BARICITINIB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Wallace, D. J.
Furie, R. A.
Tanaka, Y.
Kalunian, K. C.
Mosca, M.
Petri, M. A.
Dorner, T.
Cardiel, M. H.
Bruce, I. N.
Gomez, E.
Carmack, T.
Janes, J. M.
Linnik, M. D.
Silk, M.
Hoffman, R.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 59 - 59
[3] Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Wallace, Daniel J.
Furie, Richard
Tanaka, Yoshiya
Kalunian, Kenneth C.
Mosca, Marta
Petri, Michelle
Dorner, Thomas
Cardiel, Mario H.
Bruce, Ian N.
Gomez, Elisa
DeLozier, Amy M.
Janes, Jonathan
Linnik, Matthew D.
de Bono, Stephanie
Silk, Maria E.
Hoffman, Robert W.
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[4] POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS
Dorner, T.
Tanaka, Y.
Mosca, M.
Bruce, I. N.
Cardiel, M.
Morand, E. F.
Petri, M. A.
Silk, M.
Dickson, C.
Meszaros, G.
Issa, M.
Zhang, L.
Wallace, D. J.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 639 - 639
[5] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
Petri, Michelle
Bruce, Ian N.
Doerner, Thomas
Tanaka, Yoshiya
Morand, Eric F.
Kalunian, Kenneth C.
Cardiel, Mario H.
Silk, Maria E.
Dickson, Christina L.
Meszaros, Gabriella
Zhang, Lu
Jia, Bochao
Zhao, Youna
McVeigh, Conor J.
Mosca, Marta
LANCET, 2023, 401 (10381): : 1011 - 1019
[6] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
Morand, Eric F.
Vital, Edward M.
Petri, Michelle
van Vollenhoven, Ronald
Wallace, Daniel J.
Mosca, Marta
Furie, Richard A.
Silk, Maria E.
Dickson, Christina L.
Meszaros, Gabriella
Jia, Bochao
Crowe, Brenda
Torre, Inmaculada de la
Doerner, Thomas
LANCET, 2023, 401 (10381): : 1001 - 1010
[7] Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial
Sun, Fangfang
Wang, Hui Jing
Liu, Zhe
Geng, Shikai
Wang, Haiting
Wang, Xiaodong
Li, Ting
Morel, Laurence
Wan, Weiguo
Lu, Liangjing
Teng, Xiangyu
Ye, Shuang
LANCET RHEUMATOLOGY, 2020, 2 (04): : E210 - E216
[8] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
Hassanien, M.
Moshrif, A.
Hetta, H.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 34 - 35
[9] A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS
Montalban, Xavier
Hemmer, Bernhard
Rammohan, Kottil W.
Giovannoni, Gavin
De Seze, Jerome
Bar-Or, Amit
Arnold, Douglas L.
Sauter, Annette
Masterman, Donna
Fontoura, Paulo
Chin, Peter
Garren, Hideki
Wolinsky, Jerry S.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 17 - 17
[10] Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Wallace, Daniel J.
Kalunian, Kenneth
Petri, Michelle A.
Strand, Vibeke
Houssiau, Frederic A.
Pike, Marilyn
Kilgallen, Brian
Bongardt, Sabine
Barry, Anna
Kelley, Lexy
Gordon, Caroline
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 183 - 190

← 1 2 3 4 5 →